ES2637288T3 - N-((1H-indol-3-il)-alquil)-4-bencil)benzamida y derivados de N-((1H-pirrolo[2,3-b]piridin-3-il)-alquil)-4-bencil)benzamida como inhibidores de la agregación de alfa-sinucleína para el tratamiento de trastornos neurodegenerativos - Google Patents

N-((1H-indol-3-il)-alquil)-4-bencil)benzamida y derivados de N-((1H-pirrolo[2,3-b]piridin-3-il)-alquil)-4-bencil)benzamida como inhibidores de la agregación de alfa-sinucleína para el tratamiento de trastornos neurodegenerativos Download PDF

Info

Publication number
ES2637288T3
ES2637288T3 ES11805450.1T ES11805450T ES2637288T3 ES 2637288 T3 ES2637288 T3 ES 2637288T3 ES 11805450 T ES11805450 T ES 11805450T ES 2637288 T3 ES2637288 T3 ES 2637288T3
Authority
ES
Spain
Prior art keywords
benzamide
mmol
heterocycle
ethyl
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11805450.1T
Other languages
English (en)
Spanish (es)
Inventor
Gerard Griffioen
Tom Van Dooren
Verónica ROJAS DE LA PARRA
Sara Allasia
Arnaud Marchand
Amuri Kilonda
Patrick Chaltin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Katholieke Universiteit Leuven
reMYND NV
Original Assignee
Katholieke Universiteit Leuven
reMYND NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Katholieke Universiteit Leuven, reMYND NV filed Critical Katholieke Universiteit Leuven
Application granted granted Critical
Publication of ES2637288T3 publication Critical patent/ES2637288T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
ES11805450.1T 2010-12-13 2011-12-13 N-((1H-indol-3-il)-alquil)-4-bencil)benzamida y derivados de N-((1H-pirrolo[2,3-b]piridin-3-il)-alquil)-4-bencil)benzamida como inhibidores de la agregación de alfa-sinucleína para el tratamiento de trastornos neurodegenerativos Active ES2637288T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201021103 2010-12-13
GBGB1021103.5A GB201021103D0 (en) 2010-12-13 2010-12-13 New compounds for the treatment of neurodegenerative diseases
PCT/EP2011/072568 WO2012080221A1 (en) 2010-12-13 2011-12-13 New compounds for the treatment of neurodegenerative diseases

Publications (1)

Publication Number Publication Date
ES2637288T3 true ES2637288T3 (es) 2017-10-11

Family

ID=43567100

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11805450.1T Active ES2637288T3 (es) 2010-12-13 2011-12-13 N-((1H-indol-3-il)-alquil)-4-bencil)benzamida y derivados de N-((1H-pirrolo[2,3-b]piridin-3-il)-alquil)-4-bencil)benzamida como inhibidores de la agregación de alfa-sinucleína para el tratamiento de trastornos neurodegenerativos

Country Status (12)

Country Link
US (1) US9266832B2 (OSRAM)
EP (1) EP2651888B1 (OSRAM)
JP (1) JP6050241B2 (OSRAM)
CN (1) CN103261156B (OSRAM)
CA (1) CA2819171C (OSRAM)
DK (1) DK2651888T3 (OSRAM)
ES (1) ES2637288T3 (OSRAM)
GB (1) GB201021103D0 (OSRAM)
HR (1) HRP20171186T1 (OSRAM)
HU (1) HUE033277T2 (OSRAM)
SI (1) SI2651888T1 (OSRAM)
WO (1) WO2012080221A1 (OSRAM)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201021103D0 (en) 2010-12-13 2011-01-26 Univ Leuven Kath New compounds for the treatment of neurodegenerative diseases
GB201021104D0 (en) 2010-12-13 2011-01-26 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
US10266515B2 (en) * 2013-12-30 2019-04-23 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
NZ722487A (en) 2014-01-29 2022-04-29 Ucb Biopharma Sprl Heteroaryl amides as inhibitors of protein aggregation
CN104744353B (zh) * 2015-03-31 2017-11-24 山东友帮生化科技有限公司 2‑氨基‑3‑碘‑5‑氯吡啶的合成方法
CN105130978B (zh) * 2015-07-22 2017-11-21 中国人民解放军军事医学科学院基础医学研究所 一种化合物及其在帕金森疾病方面的应用
EP3328379B1 (en) * 2015-07-29 2021-07-28 UCB Biopharma SRL Bis-heteroaryl derivatives as modulators of protein aggregation
CN110099898B (zh) 2016-10-24 2023-07-25 优曼尼蒂治疗公司 化合物及其用途
KR20190108118A (ko) 2017-01-06 2019-09-23 유마니티 테라퓨틱스, 인크. 신경계 장애의 치료를 위한 방법
EP3573981B1 (en) 2017-01-26 2022-03-16 UCB Biopharma SRL Alkoxy bis-heteroaryl derivatives as modulators of protein aggregation
RU2019126170A (ru) 2017-01-26 2021-02-26 Юсб Байофарма Спрл Бисгетероарильные производные в качестве модуляторов агрегации белков
JP7073385B2 (ja) 2017-01-26 2022-05-23 ユーシービー バイオファルマ エスアールエル タンパク質凝集のモジュレーターとしての二環式ビス－ヘテロアリール誘導体
US20190382346A1 (en) 2017-02-28 2019-12-19 Universitat Autonoma De Barcelona (nitro-phenyl)-nitropyridine compounds for treating synucleinopathies
WO2019025424A1 (en) 2017-08-04 2019-02-07 Universitat Autonoma De Barcelona COMPOUNDS FOR TREATING SYNUCLEINOPATHIES
EP3700934A4 (en) 2017-10-24 2021-10-27 Yumanity Therapeutics, Inc. COMPOUNDS AND USES OF THESE COMPOUNDS
WO2019161917A1 (en) 2018-02-23 2019-08-29 Universitat Autonoma De Barcelona 4-substituted 1-ethenylsulfonyl-2-nitrobenzene compounds for treating synucleinopathies
BR112020019191A2 (pt) 2018-03-23 2021-01-05 Yumanity Therapeutics, Inc. Compostos e seus usos
KR20210125471A (ko) 2018-10-05 2021-10-18 안나푸르나 바이오, 인코포레이티드 Apj 수용체 활성과 관련된 병태를 치료하기 위한 화합물 및 조성물
EP3914593A4 (en) 2019-01-24 2022-11-02 Yumanity Therapeutics, Inc. CONNECTIONS AND USES THEREOF
US20230078764A1 (en) * 2019-03-22 2023-03-16 Yumanity Therapeutics, Inc. Compounds and uses thereof
US12318357B2 (en) 2019-08-02 2025-06-03 Acelot, Inc. Small molecule drugs and related methods for treatment of diseases related to TDP-43, alpha-synuclein, huntingtin's protein and tau protein oligomer formation
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3202669A (en) 1963-11-06 1965-08-24 Upjohn Co 6-methoxy-1-(3, 4, 5-trimethoxy phenyl)-9h-pyrido [3, 4-b] indole and its acid addition salts
IL130169A (en) 1999-05-27 2006-08-20 Neurim Pharma 1991 Indole derivatives, and pharmaceutical preparations, skin protection preparations, and cosmetics containing them
US6306890B1 (en) * 1999-08-30 2001-10-23 Vanderbilt University Esters derived from indolealkanols and novel amides derived from indolealkylamides that are selective COX-2 inhibitors
GB9922171D0 (en) * 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
CA2411165A1 (en) 2000-05-02 2002-12-11 Meiji Seika Kaisha, Ltd. Novel indole derivatives exhibiting chymase-inhibitory activities and process for preparation thereof
DOP2002000332A (es) 2001-02-14 2002-08-30 Warner Lambert Co Inhibidores de piridina de metaloproteinasas de la matriz
ES2502490T3 (es) 2003-02-26 2014-10-03 Sugen, Inc. Compuestos aminoheteroarílicos como inhibidores de proteín quinasas
MX2007000150A (es) 2004-07-01 2007-03-30 Univ California Inhibicion de moleculas pequenas de la interaccion del domini pdz.
US8946444B2 (en) * 2004-11-23 2015-02-03 Ptc Therapeutics, Inc. Tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control
JP2009501709A (ja) * 2005-07-12 2009-01-22 バイエル・クロツプサイエンス・エス・アー 新規ベンゾヘテロシクリルエチルベンズアミド誘導体
EP2149552A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma AG 5,6 substituierte Benzamid-Derivate als Modulatoren des EP2-Rezeptors
CA2751534A1 (en) * 2009-03-03 2010-09-10 Pfizer Inc. Novel phenyl imidazoles and phenyl triazoles as gamma-secretase modulators
GB0910003D0 (en) * 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
ES2360435B1 (es) * 2009-10-30 2012-05-04 Consejo Superior De Investigaciones Cientificas (Csic) (70%) Derivados de biss (aralquil) amino y sistemas (6+5)-heteroaromaticos y su uso en el tratamiento de patologias neurodegenerativas, incluida la enfermedad de alzheimer
WO2012042621A1 (ja) * 2010-09-29 2012-04-05 味の素株式会社 塩味増強剤
AR083855A1 (es) 2010-11-15 2013-03-27 Abbott Lab Inhibidores de nampt y rock
GB201021104D0 (en) 2010-12-13 2011-01-26 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
GB201021103D0 (en) 2010-12-13 2011-01-26 Univ Leuven Kath New compounds for the treatment of neurodegenerative diseases

Also Published As

Publication number Publication date
CA2819171C (en) 2020-02-18
US20130274260A1 (en) 2013-10-17
US9266832B2 (en) 2016-02-23
SI2651888T1 (sl) 2017-10-30
HRP20171186T1 (hr) 2017-10-20
JP2013544872A (ja) 2013-12-19
EP2651888B1 (en) 2017-05-17
HUE033277T2 (en) 2017-11-28
JP6050241B2 (ja) 2016-12-21
DK2651888T3 (en) 2017-08-28
CA2819171A1 (en) 2012-06-21
CN103261156A (zh) 2013-08-21
WO2012080221A1 (en) 2012-06-21
EP2651888A1 (en) 2013-10-23
GB201021103D0 (en) 2011-01-26
CN103261156B (zh) 2016-12-28

Similar Documents

Publication Publication Date Title
ES2637288T3 (es) N-((1H-indol-3-il)-alquil)-4-bencil)benzamida y derivados de N-((1H-pirrolo[2,3-b]piridin-3-il)-alquil)-4-bencil)benzamida como inhibidores de la agregación de alfa-sinucleína para el tratamiento de trastornos neurodegenerativos
JP6689805B2 (ja) カテプシンｃの置換２−アザ−ビシクロ［２．２．１］ヘプタン−３−カルボン酸（ベンジル−シアノ−メチル）−アミド阻害剤
ES2702951T3 (es) Inhibidores de quinasas dependientes de ciclina 7 (cdk7)
CN103038229B (zh) 杂芳基化合物及其使用方法
EP2651887B1 (en) N-(2-(5-substituted-1H-indol-3-yl)ethyl)biphenyl-4-carboxamide derivatives and related compounds as Tau-aggregation induced toxicity inhibitors for the treatment of neurodegenerative disorders
BR112015009168B1 (pt) Composto de fórmula estrutural xi ou um sal do mesmo, uso de um composto e composição farmacêutica
CN104725359B (zh) 取代的哌嗪化合物及其使用方法和用途
JP7405834B2 (ja) ピリジニルメチレンピペリジン誘導体及びその使用
BRPI0713187A2 (pt) método de inibir rho-quinase, método de tratamento de doença mediada por rho-quinase, composto e composição farmacêutica
CN104163813B (zh) 取代的吲哚化合物及其使用方法和用途
CN105566321B (zh) 杂芳化合物及其在药物中的应用
CN105085482B (zh) 取代的哌嗪化合物及其使用方法和用途
JP2010526027A (ja) プリン誘導体
US9598401B2 (en) Substituted heteroaryl compounds and methods of use thereof
JP2017510657A (ja) Ｍｉｆ阻害剤
CN111004214A (zh) 吡啶酰基哌啶衍生物及其用途
CN105367474A (zh) 吲哚啉类衍生物及其在药物上的应用
HK40083035B (zh) Parp7抑制剂及其用途
TW202540096A (zh) 靶向降解雄激素受體的雙功能嵌合體的雜環化合物及其用途
HK1192224A (en) N-((1h-indol-3-yl)-alkyl)-4-benzyl)benzamide and n-((1h-pyrrolo[2,3-b]pyridin-3-yl)-alkyl)-4-benzyl)benzamide derivatives as alpha synuclein aggregation inhibitors for the treatment of neurodegenerative disorders
HK1192224B (en) N-((1h-indol-3-yl)-alkyl)-4-benzyl)benzamide and n-((1h-pyrrolo[2,3-b]pyridin-3-yl)-alkyl)-4-benzyl)benzamide derivatives as alpha synuclein aggregation inhibitors for the treatment of neurodegenerative disorders
BR112020006456B1 (pt) Compostos químicos, composição farmacêutica e seus usos para tratar uma infecção por vírus da hepatite b e para inibir o nível do antígeno hbe ou hbs em um hbsag de mamífero in vitro
BR112020006456A2 (pt) compostos químicos